Celgene Corporation to Webcast at Two Upcoming Investor Conferences and the American College of Rheumatology
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company’s
web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Wednesday, November 14, 2012, Celgene will present at the Credit
Suisse Healthcare Conference at 5:30 p.m. ET.
On Tuesday, November 27, 2012, Celgene will present at the Piper
Jaffray 24th Annual Healthcare Conference at 9:00 a.m. ET.
Celgene will alsohost a webcast of an investor event at the
American College of Rheumatology (ACR) meeting on Tuesday, November 13
at 6:00 p.m. ET. Members of Celgene’s management team and clinical
investigators will discuss the PALACE-1 results in psoriatic arthritis.
The meeting will be webcast live and will be available in the investor
relations section of the Company’s web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of novel therapies for the
treatment of cancer and inflammatory diseases through gene and protein
regulation. For more information, please visit the company’s Web site at www.celgene.com.
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
In addition to financial information prepared in accordance with U.S.
GAAP, this press release also contains adjusted financial measures that
we believe provide investors and management with supplemental
information relating to operating performance and trends that facilitate
comparisons between periods and with respect to projected
information. These adjusted measures are non-GAAP and should be
considered in addition to, but not as a substitute for, the information
prepared in accordance with U.S. GAAP. We typically exclude certain GAAP
items that management does not believe affect our basic operations and
that do not meet the GAAP definition of unusual or non-recurring items.Other companies may define these measures in different ways. See
the attached Reconciliations of GAAP to adjusted Net Income for
explanations of the amounts excluded and included to arrive at adjusted
net income and adjusted earnings per share amounts for the three- and
nine-month periods ended September 30, 2012 and 2011, and for the
projected amounts for the year ending December 31, 2012.
Celgene Corporation Jacqualyn A. Fouse, Ph.D, 908-673-9956 EVP,
Chief Financial Officer or Patrick E. Flanigan III,
908-673-9969 VP, Investor Relations